BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare I&I Disease Analysis: Psoriatic Arthritis

March 30, 2022

Approved to treat psoriatic arthritis in 2005, AbbVie’s Humira has long enjoyed status as the preferred first-line biologic due to its efficacy in joint manifestations, along with an ability to help clear the skin, and physicians’ extensive experience with the drug. Biosimilars of Humira have been approved but are not expected to be launched in the US until 2023. In Europe, biosimilar versions of adalimumab were first launched in 2018. 

There are relatively few drugs in the pipeline for psoriatic arthritis, with many labels for psoriatic arthritis being extensions from other indications, like psoriasis. 

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Psoriatic Arthritis (PA)
Back to the top Back to the top